StockData
Hyperfine, Inc. logo

Hyperfine, Inc. (HYPR) company profile

HYPRNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3028% below fair value
$0.56−0.05 (-7.95%)

Close on Nov 17, 2026Market cap $59.56MP/E –Yield –

About Hyperfine

Electromedical & Electrotherapeutic Apparatus, SIC 3845

The health technology company develops and commercializes artificial intelligence-powered portable magnetic resonance imaging solutions. Its principal offering is the Swoop Portable MR Imaging System, an ultra-low-field brain scanner integrated with deep learning software designed to deliver neuroimaging directly at the point of care, including bedside hospital settings and outpatient clinics. Operating alongside the scanner hardware, the business provides proprietary software sequences, annual service agreements, and a subscription-based research data platform. The company primarily serves healthcare providers, including critical care units, emergency departments, inpatient hospital facilities, and office-based neurology practices, as well as international clinical providers.

Direct commercial activities occur primarily within the United States, complemented by authorized third-party distributor relationships that serve international healthcare institutions across Canada and select markets in Europe, Asia, Oceania, and the Middle East. Beyond the domestic market, regulatory marketing authorizations and product approvals span Canada, Australia, New Zealand, India, the United Kingdom, and the European Union.

Summary of the business section of Hyperfine's latest annual report, written by StockData.

Company profile

Company

Legal name
Hyperfine, Inc.
Founded
2014
Headquarters
Guilford, CT
Address
351 New Whitfield Street 06437
Phone
(866) 796-6767
Employees
102, Dec 31, 2025
Industry
Electromedical & Electrotherapeutic Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
GRANT THORNTON LLP, San Jose, California

Stock & identifiers

Ticker
HYPR
Former tickers
HCAQ until Dec 28, 2021
Exchange
Nasdaq
IPO date
Jan 28, 2021
Shares outstanding
106M, Aug 3, 2026
Public float
$44.20M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1833769
CUSIP
44916K106
ISIN
US44916K1060
FIGI
BBG00YVTN9J2
Share class FIGI
BBG00YVTN9K0
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Maria SainzPresident and CEO, Director789,586
Brett HaleCFO and CAO592,420
Thomas TeisseyreChief Operating Officer671,256
Dan WoltermanDirector19,586
Ruth A. FattoriDirector20,477
Jonathan M. RothbergDirector17,062,534
John T. DahldorfDirector19,586

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payTotalvs. prior year
Maria Sainz
President and Chief Executive Officer
$582.23K–$314.59K$896.82K-60%
Brett Hale
Chief Administrative Officer and Chief Financial Officer
$449.82K$214.80K$135.02K$799.63K-24%
Thomas Teisseyre
Chief Operating Officer
$449.82K$214.80K$135.02K$799.63K-24%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Jan 28, 2021
Offer price
$10.00
Exchange
Nasdaq
First trading day
Jan 27, 2021
First-day close
$10.01+0.1%
Lock-up ends (est.)
Jul 26, 2021

“This is an initial public offering of our Class A ordinary shares, par value $0.0001 per share, which we refer to as our public shares, at an initial public offering price per share of $10.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 15, 2026, we had 102 employees, all of whom were full-time employees and of whom 24 work in sales, marketing, and commercial support, 56 work in research, development, clinical, technical assistance, supply chain, operations and logistics and 22 work in general and administrative capacities.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?